Raquel Guimarães-Costa

Raquel Guimarães-Costa

Auto-generated profile, based on publicly available information

Raquel Guimarães-Costa

National Referral Center for rare Neuromuscular Diseases, Institut Hospitalo-Universitaire de Neurosciences, University Hospital Pitié-Salpêtrière and University Pierre et Marie Curie (Paris VI), Paris, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AFAbdallah FAYSSOIL
Abdallah FAYSSOIL
AOAdam Ogna
Adam Ogna
CCCendrine Chaffaut
Cendrine Chaffaut
SCSylvie Chevret
Sylvie Chevret
RGRaquel Guimarães-Costa
Raquel Guimarães-Costa
DADjillali Annane
Djillali Annane
Type 2C and 2D limb girdle muscular dystrophies (LGMD) are a group of autosomal recessive limb girdle muscular dystrophies manifested by proximal myopathy, impaired respiratory muscle function and cardiomyopathy. The correlation and the prognostic impact of respiratory and heart impairment are poorly described. We aimed to describe the long-term cardiac and respiratory follow-up of these patients and to determine predictive factors of cardio-respiratory events and mortality in LGMD 2C and 2D. We reviewed the charts of 34 LGMD patients, followed from 2005 to 2015, to obtain echocardiographic, respiratory function and sleep recording data. We considered respiratory events (acute respiratory failure, pulmonary sepsis, atelectasis or pneumothorax), cardiac events (acute heart failure, significant cardiac arrhythmia or conduction block, ischemic stroke) and mortality as outcomes of interest for the present analysis. A total of 21 patients had type 2C LGMD and 13 patients had type 2D. Median age was 30 years [IQR 24–38]. At baseline, median pulmonary vital capacity (VC) was 31% of predicted value [20–40]. Median maximal inspiratory pressure (MIP) was 31 cmH2O [IQR 20.25–39.75]. Median maximal expiratory pressure (MEP) was 30 cm H2O [20–36]. Median left ventricular ejection fraction (LVEF) was 55% [45–64] with 38% of patients with LVEF <50%. Over a median follow-up of 6 years, we observed 38% respiratory events, 14% cardiac events and 20% mortality. Among baseline characteristics, LVEF and left ventricular end diastolic diameter (LVEDD) were associated with mortality, whilst respiratory parameters (VC, MIP, MEP) and the need for home mechanical ventilation (HMV) were associated with respiratory events. In our cohort of severely respiratory impaired type 2C and 2D LGMD, respiratory morbidity was high. Cardiac dysfunction was frequent in particular in LGMD 2C and had an impact on long-term mortality. ClinicalTrials.gov NCT02501083

16 March 2015 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
JLJean-Marc Léger
Jean-Marc Léger
RGRaquel Guimarães-Costa
Raquel Guimarães-Costa
RFRuxandra Iancu Ferfoglia
Ruxandra Iancu Ferfoglia
Multifocal motor neuropathy (MMN) is a rare and disabling disease. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis, although underlying mechanisms in MMN seem to be very specific, mainly because of the presence of IgM anti-GM1 serum antibodies and the dramatic response to intravenous immunoglobulins (IVIg). The origin of antiganglioside antibodies and the way in which they act at the molecular level remain unclear. Several studies have demonstrated the key role of complement activation in the underlying mechanisms of MMN, as well as in animal models of acute motor axonal neuropathy (AMAN). Deposition of the membrane attack complex may disrupt the architecture of the nodes of Ranvier and paranodal areas, causing local disruption of nodal sodium-channel clusters. In patients with MMN, muscle weakness is the consequence of conduction blocks (CB), which leads to secondary axonal degeneration, consequently the aim of the treatment is to reverse CB at early stages of the disease. High-dose immunoglobulin is to date the only therapy which has proven efficacy in MMN patients in providing transient improvement of muscle strength, but long-term follow-up studies show a progressive motor decline. Therefore, other therapies are needed to improve the conduction nerve properties in long-term design. The reduction of complement activation and more generally the gain in paranodal stabilization could be directions for future therapeutic strategies.

1 January 2016 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
JLJean-Marc Léger
Jean-Marc Léger
RGRaquel Guimarães-Costa
Raquel Guimarães-Costa
CMCristina Muntean
Cristina Muntean

1 September 2007 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
RGRaquel Guimarães-Costa
Raquel Guimarães-Costa
MGMaria Beatriz Guimarães-Costa
Maria Beatriz Guimarães-Costa
LPLeonardo Pippa-Gadioli
Leonardo Pippa-Gadioli
AWAlfredo Weltson
Alfredo Weltson
WUWalter Adriano Ubiali
Walter Adriano Ubiali
NCNorberto Cysne Coimbra
Norberto Cysne Coimbra

1 March 2016 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
PDF file
RFRuxandra Iancu Ferfoglia
Ruxandra Iancu Ferfoglia
RGRaquel Guimarães‐Costa
Raquel Guimarães‐Costa
KVKarine Viala
Karine Viala
LMLucile Musset
Lucile Musset
JNJean Neil
Jean Neil
JLJean‐Marc Léger
Jean‐Marc Léger

14 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RGRaquel Guimarães‐Costa
Raquel Guimarães‐Costa
GFGorka Fernández‐Eulate
Gorka Fernández‐Eulate
KWKarim Wahbi
Karim Wahbi
FLFrance Leturcq
France Leturcq
EMEdoardo Malfatti
Edoardo Malfatti
TSTanya Stojkovic
Tanya Stojkovic